Results 61 to 70 of about 4,153 (212)

PLA2R‐Positive Membranous Nephropathy and AA Amyloidosis in an Ethiopian Patient With Chronic Hepatitis B: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT The coexistence of primary phospholipase A2 receptor positive membranous nephropathy and AA amyloidosis in a patient with chronic hepatitis B is an exceedingly rare triad presenting a profound diagnostic and therapeutic challenge. A 38‐year‐old Ethiopian man with nephrotic syndrome and chronic hepatitis B had dual pathology on renal biopsy ...
Betelhem Abreham, Leja Hamza, Azeb Kebede, Daniel Rebuma Bekele, Zekarias Amdemariam   +4 more
wiley   +1 more source

Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review

Терапевтический архив, 2023
Chronic kidney disease (CKD) is one of the most common complications of diabetes mellitus and an independent risk factor for cardiovascular disease. Despite guideline-directed therapy of CKD in patients with type 2 diabetes, the risk of renal failure and
Vladimir V. Salukhov, Minara S. Shamkhalova, Alla V. Duganova   +2 more
doaj   +1 more source

Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF:A Prespecified Analysis of FINEARTS-HF [PDF]

Background: An initial decline in estimated glomerular filtration rate (eGFR) often leads to reluctance to continue life-saving therapies in patients with heart failure (HF).
Bauersachs, Johann, Brinker, Meike, Claggett, Brian L., Desai, Akshay S., Henderson, Alasdair D., Jhund, Pardeep S., Kerr Saraiva, Jose Francisco, Lam, Carolyn S.P., Linssen, Gerard C.M., Mares, Jon W., Matsumoto, Shingo, McMurray, John J.V., Pitt, Bertram, Scalise, Andrea, Schloemer, Patrick, Senni, Michele, Solomon, Scott D., Troughton, Richard, Udell, Jacob A., Vaduganathan, Muthiah, Viswanathan, Prabhakar, Voors, Adriaan A., Zannad, Faiez   +22 more
core   +1 more source

Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4344-4351, May 2026.
ABSTRACT Aims Kidney and cardiovascular diseases are highly prevalent among patients with Type 1 diabetes. To date, no randomised clinical trial has reported on the impact of novel cardio‐kidney‐metabolic (CKM) therapies (GLP‐1RA and SGLT2i) on kidney function in this population.
M. Luiza Caramori, Enrico Repetto, Christopher Perkins, Ambarish Pandey, Peter Rossing   +4 more
wiley   +1 more source

Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies [PDF]

Introduction Proteinuria is a modifiable risk factor for chronic kidney disease (CKD) progression in children. Finerenone, a selective, non-steroidal, mineralocorticoid receptor antagonist (MRA) has been approved to treat adults with CKD associated with ...
Breitenstein S., Iveli P., Kang H. G., Litwin M., Montini G., Potts J., Scalise A., Schaefer F., Schreuder M. F., Scott H., Walle J. V., Warady B. A., Zaritsky J.   +12 more
core   +1 more source

Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China

Renal Failure
Aims Finerenone has been approved for treating diabetic kidney disease (DKD) with reducing cardiorenal risk. Real-world data on finerenone treatment for the management of DKD are presently lacking. This study aimed to investigate the effect of finerenone
Jingying Zhou, Le Kang, Chenjie Gu, Xinwei Li, Xianan Guo, Ming Fang   +5 more
doaj   +1 more source

Finerenone and new-onset diabetes in heart failure:a prespecified analysis of the FINEARTS-HF trial [PDF]

Background: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA1c levels and new-onset diabetes are conflicting. We aimed to examine the effect of oral finerenone, compared with placebo, on incident diabetes in the Finerenone Trial
, Amarante, Flaviana, Butt, Jawad H., Claggett, Brian L., Desai, Akshay S., Henderson, Alasdair D., Jhund, Pardeep S., Kolkhof, Peter, Lam, Carolyn S.P., McMurray, John J.V., Pitt, Bertram, Schloemer, Patrick, Senni, Michele, Shah, Sanjiv J., Solomon, Scott D., Vaduganathan, Muthiah, Viswanathan, Prabhakar, Voors, Adriaan A., Zannad, Faiez   +18 more
core   +2 more sources

Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2953-2961, April 2026.
Abstract Objective People with chronic kidney disease (CKD) and diabetes are at high risk of cardiovascular disease (CVD). Aortic pulse wave velocity (Ao‐PWV) is an independent predictor of CVD. Cardiovascular outcome trials (CVOTs) with glucagon like peptide‐1 receptor agonist (GLP‐1 RA) class demonstrate notable differences, with lixisenatide having ...
Nikolaos Fountoulakis, Panagiotis Pavlou, Dimitra Stathi, Aicha Goubar, Antonella Corcillo, Maria Flaquer, Salma Ayis, Luigi Gnudi, Janaka Karalliedde   +8 more
wiley   +1 more source

Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection. [PDF]

, 2022
The renin-angiotensin-aldosterone system is a neurohormonal system responsible for maintaining homeostasis of fluid regulation, sodium balance, and blood pressure.
Aronow, Wilbert S, Goel, Akshay, Gupta, Rahul, MD, Hajra, Adrija, Maitz, Theresa, DO, Nguyen, Catherine, Parfianowicz, Dominic, DO, Shah, Swara, DO, Sreenivasan, Jayakumar, Vyas, Apurva, MD   +9 more
core   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3137-3145, April 2026.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source